Better Coronavirus Vaccine Stock: BioNTech vs. Moderna

There are now 23 coronavirus vaccine candidates in clinical testing, according to the World Health Organization. Four of them use an approach that involves engineering messenger RNA (mRNA) sequences, which in turn direct ribosomes in human cells to produce a protein identical to one found on the surface of SARS-CoV-2 -- in other words, an antigen to the virus that causes COVID-19.

BioNTech (NASDAQ: BNTX) and Moderna (NASDAQ: MRNA) developed two of those four mRNA COVID-19 vaccine candidates. So far, Moderna's efforts have received a lot more attention than BioNTech's program has. But which of these coronavirus-focused stocks is the better pick for investors now?

Image source: Getty Images.

Continue reading

Source Fool.com